I apologize.
Maybe I'll stop, because I don't want to take up too much time. It's just to say, Madam Chair, that the international facilities we're generally partnering with—like AstraZeneca and others—were able to produce, by an order of magnitude, far more than any facility in Canada could produce.
The challenge for the companies is that technology transfer is a time-consuming effort. It isn't like getting a muffin recipe and you get the ingredients and you make it. Typically, it's six months or longer. You have to do small lots of the vaccine and prove you can do it. The technicians from the company have to be on site to check everything. When these companies were allocating effort, they had to focus on facilities that could produce massive amounts, not smaller-scale facilities that could produce a smaller amount.
Thank you.